Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soyaklin Forte is an oral phytomedicine developed by Juvenor Pharmaceuticals and marketed in collaboration with Piramal Enterprises. It is specifically formulated with soy isoflavones, which are naturally occurring phytoestrogens used to manage the climacteric symptoms associated with menopause, such as hot flashes, night sweats, and mood disturbances. The active components, primarily genistein and daidzein, function as selective estrogen receptor modulators (SERMs). These compounds exhibit a preferential binding affinity for estrogen receptor beta (ER-beta) over estrogen receptor alpha (ER-alpha), allowing them to exert estrogenic effects in tissues like bone and the cardiovascular system while potentially acting as antagonists or weak agonists in the breast and uterus. This profile makes it a common alternative to traditional hormone replacement therapy (HRT) for the prevention of postmenopausal osteoporosis and the relief of vasomotor symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Soyaklin Forte.